Compare ORMP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | AGEN |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.9M | 208.2M |
| IPO Year | 2010 | 1999 |
| Metric | ORMP | AGEN |
|---|---|---|
| Price | $4.15 | $6.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 252.6K | ★ 8.4M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | 100.00 |
| EPS | 0.91 | ★ 1.02 |
| Revenue | $2,000,000.00 | ★ $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $4.43 | $5.86 |
| Revenue Growth | 49.25 | ★ 89.95 |
| 52 Week Low | $1.98 | $2.71 |
| 52 Week High | $5.19 | $8.70 |
| Indicator | ORMP | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 71.06 |
| Support Level | $3.87 | $3.09 |
| Resistance Level | $4.22 | $8.70 |
| Average True Range (ATR) | 0.17 | 0.77 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 47.06 | 54.02 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.